mRNA vaccine against influenza: first tests are showing results

Deepak Gupta
Deepak Gupta December 14, 2021
Updated 2021/12/14 at 5:57 PM

In the context of the global pandemic, all kinds of vaccines made headlines. He was also part of the party mRNA vaccine of the US company Moderna. The group is now working on a similar means as a Flu vaccination. Moderna has now apparently successfully completed the first phase of its studies on the new drug.

Moderna is working on a new flu vaccination

The biotech company’s share price fell recently after the mRNA vaccine was shown to be ineffective against four strains of flu. Reports drew the public’s attention to the study at the worst possible hour. Now it seems like Moderna has another success to celebrate.

A press release reveals the results of a phase 1 study with the influenza vaccine candidate mRNA-1010. He is said to have asserted himself against the A / H1N1, A / H3N2, B / Yamagata and B / Victoria strains. The phase 2 study for mRNA-1010 has already been fully recruited and preparations for the phase 3 study are also underway.

“Even before the COVID-19 pandemic, around three million people died from respiratory infections each year, and many more are hospitalized or become ill because of these viruses. Our goal at Moderna is to limit this condition with a single dose, annual booster pan-respiratory vaccine that is adapted to circulating strains of SARS-CoV-2, seasonal flu and RSV. “

Stéphane Bancel, Managing Director of Moderna

Important milestone

The results of the flu vaccination from phase 1 would represent an important milestone on the way to the new mRNA vaccine, said Bancel. It is encouraging to see “that the study participants […] achieved robust increases in geometric mean antibody titers against H1N1 and H3N2 ”. These are the strains that are responsible for the vast majority of mortality.

“We believe our mRNA platform is well positioned to meet the significant unmet need in seasonal flu, as demonstrated by our new tetravalent candidates mRNA-1011 and mRNA-1012, which we believe will cover the strains expand and give health authorities more options. “

Stéphane Bancel, Managing Director of Moderna

Source: Moderna

Share this Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *